ArticleNature immunology2010
The activating receptor NKp46 is essential for the development of type 1 diabetes.
Article in Nature immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 172 citations in OpenAlex.
- IL-21 mediates crosstalk between T cells and NK cells during the remission of type 1 diabetes.Nature metabolism · 2026Article
- Genome-Wide Aggregated Trans Effects Analysis for Circulating Proteins Indicates a Key Role of Immune Checkpoints in Type 1 Diabetes.Diabetes · 2025Article
- Emerging role of natural killer cells in non-AIDS comorbidities during suppressive antiretroviral therapy.Current opinion in HIV and AIDS · 2025Review
- Cell-targeted PD-1 agonists are potent NK-cell inhibitors.Frontiers in immunology · 2025Article
- Changes in circulating NK and innate-like T cells in type 1 and type 2 diabetes.Frontiers in immunology · 2025Article
- Advancements in the Study of the Immune Molecule NKp46 in Immune System-related Diseases.Clinical reviews in allergy & immunology · 2024Review
- Mechanism exploration and biomarker identification of glycemic deterioration in patients with diseases of the exocrine pancreas.Scientific reports · 2024Article
- Genome-wide aggregated trans-effects on risk of type 1 diabetes: A test of the "omnigenic" sparse effector hypothesis of complex trait genetics.American journal of human genetics · 2023Article
- Natural killer cells- from innate cells to the discovery of adaptability.Frontiers in immunology · 2023Review
- The effect of spermidine on autoimmunity and beta cell function in NOD mice.Scientific reports · 2022Article
- Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications.Stem cell research & therapy · 2022Review
- Administration of Human Derived Upper gut Commensal Prevotella histicola delays the onset of type 1 diabetes in NOD mice.BMC microbiology · 2022Article
- Innate immunity in latent autoimmune diabetes in adults.Diabetes/metabolism research and reviews · 2022Review
- Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection.Frontiers in immunology · 2022Article
- Impaired Innate Immunity in Pediatric Patients Type 1 Diabetes-Focus on Toll-like Receptors Expression.International journal of molecular sciences · 2021Article
- Type I IFN-Driven Immune Cell Dysregulation in Rat Autoimmune Diabetes.ImmunoHorizons · 2021Article
- High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis.Clinical rheumatology · 2021Article
- Natural killer cells in inflammatory autoimmune diseases.Clinical & translational immunology · 2021Review
- Natural Killer Cells as Key Mediators in Type I Diabetes Immunopathology.Frontiers in immunology · 2021Review
- Low-dose interleukin-2-loaded nanoparticle effect on NK and T-reg cell expression in experimentally induced type 1 diabetes mellitus.Przeglad gastroenterologiczny · 2021Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanism of action of natural killer (NK) cells in type 1 diabetes is still unknown. Here we show that the activating receptor NKp46 recognizes mouse and human ligands on pancreatic beta cells. NK cells appeared in the pancreas when insulitis progressed to type 1 diabetes, and NKp46 engagement by beta cells led to degranulation of NK cells. NKp46-deficient mice had less development of type 1 diabetes induced by injection of a low dose of streptozotocin. Injection of soluble NKp46 proteins into nonobese diabetic mice during the early phase of insulitis and the prediabetic stage prevented the development of type 1 diabetes. Our findings demonstrate that NKp46 is essential for the development of type 1 diabetes and highlight potential new therapeutic modalities for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.